Thyroid Medication Recall Upgraded to FDA's Highest Risk Level
The FDA said the tablets could be superpotent and may cause serious health effects, with about 1,900 units sold from the batch.
- On September 22, the FDA elevated the recall of Vitruvias Therapeutics thyroid tablets to a Class I designation, the agency's most serious classification, following the company's voluntary recall of lot 504950 initiated last month.
- Vitruvias Therapeutics initiated the recall after testing confirmed the medication could be 'superpotent,' or stronger than intended, potentially causing 'hyperthyroidism' and symptoms including weight loss, fatigue, and hypertension.
- The affected 'Thyroid Tablets, USP' were distributed nationwide between January 31 and September 30, 2025, with about 1,900 units sold from a batch of about 3,600, identifiable by National Drug Code 69680-166-00.
- Patients currently taking the medication should not stop without contacting a healthcare provider, the FDA advised, while Vitruvias Therapeutics stated it would notify retailers to discontinue distribution and arrange for 'destruction' of all recalled tablets.
- This recall follows separate actions taken over the summer regarding other thyroid medications, as Ohio-based Major Pharmaceuticals and North Carolina-based Accord Healthcare Inc. recalled different levothyroxine sodium products in July.
98 Articles
98 Articles
Thyroid Drug Recall Most Serious; GLP-1s and Vitamin Deficiency; New T1D Guidelines
(MedPage Today) -- The FDA designated Vitruvias Therapeutics' recall of a lot of 30-mg levothyroxine-liothyronine tablets (Thyroid Tablets) as Class I, its most serious classification. (USA Today) At least six major U.S. hospitals have shut down...
The U.S. Food and Drug Administration (FDA) issued an alert about the voluntary withdrawal of a lot of Thyroid Tablets, USP 30 mg, used to treat hypothyroidism, due to the possibility that hypothyroidism may be...
FDA: Use of Thyroid Drug May Cause Serious Harm, Death
A batch of thyroid pills just got slided with the FDA's most serious recall label. Regulators have upgraded last month's recall of one lot of 30-milligram "Thyroid Tablets, USP" from Vitruvias Therapeutics Inc. to a Class I recall, meeting that use of the drug could lead to serious harm or...
FDA Raises Thyroid Tablet Recall To Most Serious Level
FDA Raises Thyroid Tablet Recall To Most Serious Level Authored by Jack Phillips via The Epoch Times, The Food and Drug Administration this week elevated a prescription thyroid medication recall to its most serious classification because the medication is too potent. Medications are stored on shelves at a pharmacy in Los Angeles on May 12, 2025. Eric Thayer/Getty ImagesSeveral weeks ago, Vitruvias Therapeutics said in a notice published by the F…
Coverage Details
Bias Distribution
- 89% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
